THE USE OF CARBAMAZEPINE IN PATIENTS WITH MANIC DEPRESSIVE ILLNESS by Sethi, B.B. et al.
Indian J. Psychiat. (1983), 25(1), 23—28 
THE USE OF CARBAMAZEPINE IN PATIENTS WITH MANIC DEPRESSIVE 
ILLNESS 
B.B. SETHI,' M.B.B.S., D.Sc, Psych. (Penn.), F.R.C. Psych., Dip. Am B. Psych., F.A.P.A. 
J. K. TRIVEDI,* M.D. (Psychiat.) 
R. K. SINGH," M.D. (Psychiat.) 
SUMMARY 
16 cases of affective disorder were studied. 8 patients received carbamazepinc and 8 received either 
chlorpromazine or imipramiiie. Ratings were carried out on the Hamilton Rating Scale for Depre-
sion, Bech Rafaelsen Mania Rating scale and a side-effects sysmtom check list. Garbamazepine was found 
to be an effective treatment for affective disorders, possessing both anti-manic as well as anti-depressant 
properties. 
The fact that carbamazepine an 
iminodibenzyl derivative and an estab-
lished antiepileptic agent, may be useful 
in psychiatric disorders was noted many 
years ago (Marjerrison et al,. 1968). 
Most of the early leports were of uncon-
trolled clinical trials. The psychotropic 
effects of carbamazepine have, since, 
been studied extensively (Pryse-Phillips 
& Jeavens, 1970; Rodin et al., 1974). 
Dalby (1975) in a review of 40 reports 
found that 50% of 2500 patients with 
epilepsy improved psychiatrically when 
given carbamazepine. The phasic dis-
orders of epilepsy resembling functional 
psychiatric syndromes, especially manic-
depressive illness and schizophreniform 
psychoses, often show a dramatic response 
to carbamazepine. Sometimes this res-
ponse is without a concomitant reduc-
tion in the frequency of seizures (Dalby, 
1975). Recent investigations, therefoie, 
have been directed towards delineation 
of the possible tole of carbamazepine 
in the management of affective disorders. 
Investigators, mainly from Japan and the 
U. S. A. have suggested that carbama-
zepine may be effective in manic depre-
ssive illness (Folks et al., 1982; Ballenger 
& Post, 1980; Okuma et al., 1979; and 
Takezaki & Hanaoka, 1971). Okuma 
and associates (1979) compared the anti-
manic efficacy of carbamazepine and 
chlorpromazine. They reported an over-
all improvement of the patients on Gar-
bamazepine to be about 70%. 
Recent teports have also shown that 
carbamazepine maybe effective in affec-
tive disorders in a synergistic fashion with 
lithium. Forrest (1982), in a case report, 
described the case of a 45 years old 
man with Right Hemisphrectomy (done 
for intractable epilepsy) who developed 
a rapid cycling bipolar illness. This 
responded well only when carbamazepine 
was added to lithium. A similar report 
of synergism between carbamazepine and 
lithium has been described by Lipinski 
et al (1982). 
Ballenger and Post (1976, 1978) 
have postulated a kindling model of 
affective psychoses, wherein cumulative 
bioelectrical changes, particularly in the 
limbic area, secondary to repeated bio-
chemical or psychological stresses, could 
result in abnormal limbic neuronal sen-
sitization and major psychiatric distur-
bances. Garbamazepine has been 
demonstrated to suppress after discharges 
(Koella et al., 1975) and spontaneous and 
induced seizure discharges preferentially 
in limbic areas over other cortical areas 
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(Dciiictre-oi & Julicn, 1974). The neti-
rophysiologic actions of carbamazepire 
could be efficac ions in trailing the 
"kindled'' affective disorders as populated 
by Ballenger .n;d Poa (1980). 
Further, a recent tevievv of wo.Id 
liter,nine suggcus dial from 30-40% of 
patients treated prophylactically with 
liihinm do not te-spo id ;Bunt.cy, 1982). 
Thetefore, it is «:-.><;nii.iI IO develop alter-
natives io liihiiun carbonate. Cnrba-
ma/.epine would .'-ecu to fill litis need. 
However, precntly the. e is an urgent 
need lo evaluate carbamazepine in a 
larger population of patients to find out 
as to which pilient- respond IO carba-
miziph.e (CBZ: and whctlici it is effec-
tive in patients who do rot respond 
to lithium. Its synergistic and effica-
cious combination with Lithium also 
needs to be looked into. Hence, keeping 
in view the alveuce of any Italian reports 
on (tiis topic, we decided to carry out a 
pilot invent iga tio t iiro ihe io!e ofcarba-
mazipine in M.mic-Depi e sue Illness. 
MATERIA!, AND METHODS 
An opci' study mi the effects of 
Carb uuazepino w'ts planne I. Patients 
diaguo ed as eithct M i jo; Deptcssive 
Disorder or Bipolar I)i>order according 
io DSM-III were included into ihe 
siudy. Paiicits with depletion were 
then startel on cithc Imipr.mhec (IMI) 
or C it bamazepii.c VCBZ: according to 
a randomization M'hedttle. Sijnilaily, 
manic patients were started randomally 
either on chlnrpi omazine (CPZ; or C.'BZ 
The affective states were moui'o:ed 
throughout tie studv period .'on days 
0, 3, 14, 21 and 28 of four weeks. 
Patients ov. IMI wc e given 7.1 jug. IMI 
pet day to- 3 day*, which was then 
incici-ed ;o 150 mg. for 14 days. If at 
ihe end of day 14 the.e was less than 
70",, impt oveme-it on the Hamihoii 
Rating Scale for Depression, then the 
dose was ii ctc.^cd to 200 mg./day. 
Patients on CPZ were given 600 mg. of 
CPZ for 3 days which was then increased 
to 1000 jug. till day 14. If there was 
less than 70% improvement on the Bech-
Rafaelsen Mania Rating Scale then the 
doc was increased to 1300 mg/day. 
All patients on CBZ were given 600 mg. 
of CBZ for 3 days. Doe was then 
increased to 1000 mg/day till day '4. 
If there was less than 70% ijnpiovemeiit 
then the dose was increased to 1600 
mg/day. The ratings were carried out 
on the following instruments: (l) The 
Bcch-Rafaels.cn Mania Rating Scale, (ii) 
Hamilton Rating Scale for Depression, 
(iii
1) Side-effect symptom Check-list, (iv) 
Clinical Global Implosion Schedule. All 
patients were between 18 and 55 years 
of age. Pregnancy and evidence of any 
major physical illv.es were exclusion 
criteria. All patients wete given tho-
rough clinical physical examination a7id 
were ime-aiga ted, including complete 
blood count, plate'e. count and ECG. 
OBSERVATION'S AND RESULTS 
This is a report of 16 Cases, of which 
8 were on Carbamazepine and 8 on 
chlorpromazine or Imipramine (depen-
ding iipoi the clinical state). Of the 
8 patients on CBZ, 6 showed moderate 
to mirked improvement in their clinical 
status. Oi.e paticai (B. L.) showed only 
about 50% improvement while another 
showed m'rked side effects of CBZ which 
resulted in a discontinuation of her trial. 
This young female ^37 yrs. old) was 
diagnosed as crc of recurrent bipolar 
affective disorder, being in the depre-
ssed phase at ibe start of trial. She was 
without any side elfec's tilt d. y 5, i. e. 
ore day after ii.ocae of do e from 600 
mg. of CBZ 'o 1000 mg. From day 
5 she developed nan-en. dizzne-s ;!nd 
vomiting. On days 6 at.d 7 she was 
given lower doe. (600 mg'day of CBZ 
but there was no leohtiio:; in thee side 
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TABLE 1. Patient characteristics and response to CBZ Treatment 
SI.No. Age Sex Diagnosis Dose Alter Day 14 PT. Response to Carbaraazepine 
(per day) 
1. (K.J.)37yr. 
(BPH) 38 yr. 
1
; Dep. 
Bipolar 
Discontd. after day 8 when patient was on 1000 rug/day of 
CBZ. She developed marked dizziness, nausea, vomiting, 
loose motions and finally dehydration. Resolved after 
CBZ discontinued. 
M Mania 
Bipolar 
3. (ZH) 44 yrs. M Bipolar Mania 1000 mg. 
4. (BL) 48 yrs. 
5. (CL) 52 yrs. 
6. (SR) 45 yr. 
7. (VD) 45 yrs. 
8. (CP) 40 yr. 
1000 mg. Marked improvement in Mania apparent 
on day 14. Side ellects mild and transi-
ent. Almost completely recovered by 
day 28. 
Moderate improvement. 75% reduction in 
symptoms by day 28, S/E mild-(-Tran-
sient. 
M Major Depr. 1600 mg. Mild-moderate improvement. Only 50% 
Disorder. (appro*.) reduction in symptoms by day 
28. Developed diplopia on day 5. tran-
sient. 
M Depression 1000 mg. Marked improvement, Transient ataxia on 
Bipolar. day 7 for 1 day. 
M Major Depr. 1000 mg. Ditto—Transient ataxia, climisiness and 
blurred Vision. 
M Bipl. Mania 1000 mg. Moderate improvement. 80% reduction 
by day 28. Nausea, dizziness and blu-
rred Vision. Transient. 
M Major Depr. 1600 mg. Moderate improvement. Only about 70 % 
reduction in sysmtoms by day 28. 
Ataxia & Drowsiness transiently on the 
latter 2 occasions of increase in do?e. 
Slurred speech. Nausea also. 
quile dehydrated o-i clay 8, when it was 
decided that the drug had to be discon-
tinued and patient was managed on 
I. V. fluids for her immediate problems. 
Scores on HRSD by ead of wk. 1 had 
i:ot shown any significant alteration. 
Ratings oa the B-R Mania Rat big Scale 
and HRS for Depression showed that the 
maximum improvement occurred by day 
14 of the study period. A similar assess-
ment of patieits on either CPZ or IMI 
shows that of the 8 patients who completed 
the clinical irial. only 2 showed mild to 
moderate improvement. One of these 
2 was a patient of major Depressive 
disorder, 39 yrs. old, who manifested 
only less than 50% improvement on 
200 mg/day of IMI. This patient 
was also quite troubled by mainly dizzi-
ness and postural hypotension. Physical 
examination and laboratory investigations 
did not reveil any physical abnormality. 
Notie of the patient* on .:iiy moda-
lity of treitment showed any haemato-
logic or cardiac abnormalities during 
the trial period. The major side effects 
observed with CPZ or IMI were not 
of such an intensity so as to warrant a 
discontinuation in ;,i y patient. Amongst 
the side effects of Carbamazepine- dizzi-26 
SI. No. Age 
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TABLE 2. Patient Characteristics and Response CPZ/IMI Treatment 
Sex  Diagnosis  Medication and 
Dose after 
day 14 (per day) 
PT. Response to Medication 
1. (I.K.) 32 yr. M Bipolar Mania COZ 1300 mg. Marked improvement. EPS present through 
out. 
2. (SPS) 35 yr. M Bipolar Mania CPZ 1300 mg. Moderate improvement. 80% reduction 
by day 28. EPS and postural hypoten-
sion transient. 
3. (RPS) 39 yr. M Bipolar Mania CPZ 10000 mg. Marked improvement. Minimal side 
effects. 
4. (RK) 47 yr. F Bipolar Depre- IMI 150 mg. Moderate-Marked (85%) improvement by 
ssion. day 28. Postural hypotension transi-
ent ly. 
5. (RS) 29 yr. M Bipolar Mania CPZ 1000 mg Moderate-Marked (75%) improvement by 
day 28. 
(>. (USV) 34 yr. M Bipolar Mania CPZ 1300 mg. Only G0% reduction by day 28. Frequent 
concomitant need for sedation. Side 
Effects minimal. 
7. (R.S.A.) 44 yr. M Major Depre- IMI 200 mg. Marked improvement by day 28. Postural 
ssion. hypotension ttransicntly in 3rd week. 
8. (R.S.S.) 39 yr. M Major Depre- IMI 200mg. Less than ")0% improvement by day 28. 
ssion. Side elTccts (postural hypotension, dizzi-
ness), quite prominent. No cardiac 
abnormalities on ECG. 
TABLE 3. Side effects of carbamazepine in 
8 Patients of M. D. Illness 
Symptom 
1. Diz/iness 
2. Nausea 
3. Ataxia 
4. Diplopia 
5. Blurred Vision 
t>. Drowsiness 
7. Clumsiness 
8. Slurred Speech 
9. Vomiting 
No. of Patients 
ness and nausea were the ones most 
commonly observed. Usual time of on-
set of side-effects was from day 4 on-
wards and usually disappeared on the 
same dose after a i;ap of about 2-5 days. 
3 Patients also developed mild ataxia and 
tremors which were transicat. 2 patients 
complained of blurred vision and on 
examination aho had definite diplopia. 
This side-effect was aho transient in both 
subjects. Drowsiness, slurred speech, 
clumsiness and vomiting were tio'ed 
in 1 patient e.ich. No.ie of the patients 
deve'oped any skin rash, congnitive im-
pairment, confusion- weakness and aching 
ill legs, paivc-.lhcs.ias or cardiac arrhy-
thmias (being the other commonly repor-
ted side-effects of CBZ). One patient USE OF CARBAMAZEPINE IN PATIENTS WITH MANIC DEPRESSIVE ILLNESS 27 
developed a doubtful postural hypoten-
sion, noted only on otie occasion at 
night by the resident on emergency duty. 
Subsequent monitoring next morning 
or thereafter did not reveal any .such 
finding. In the night there was a sys-
tolic difference of 24 mm. of Hg and a 
diastolic difference of 10 mm. of Hg. 
No patient on GPZ manifested any extra-
pyramidal side effects and drowsiness/ 
sedation was uncommon. Rarely, 
patients on GBZ were needed to be given 
concomitant medication, the side effects 
being managed usually on the same 
dose or a slight- transient reduction of the 
same. Most patients on GPZ needed 
antiparkinsonian medication. In this 
study 'marked' improvement was usually 
attributed to patients manifesting over 
90% reduction in ratings on the scales, 
irrespective of the side-effects. A patient 
manifesting over 70% improvement was 
considered as 'moderately' improved. 
DISCUSSION 
This report is the first from our 
country regarding the efficacy of Carba-
mazepine in Affective Disorders. This 
is an ongoing study and an initial, pilot 
investigation at our centre where in we 
are comparing the efficacy of GBZ with 
established psychotropic agents (GPZ 
& IMI) in an open study design. The 
initial impression given by this trial 
indicates GBZ to be at least as effective as 
IMI/GPZ in Depression/Mania. Prophy-
lactic effects were not studied in this 
trial. Side effects were not found to be 
limiting except in one out of 8 patients. 
Garbamazepine has a ring-like struc-
ture similar to that imipramine and it 
has been in use since the late 1950s as 
the principal treitme.it for trigermin.il 
neuralgia and since 1962 for psychomotor 
epilepsy. Its side effects which are most 
frequently reported rarely necessitate 
discontinuation of treatment (Parsonage, 
1975). Side effects are leportcd to be 
minimized if the increase in dosage is 
slow/gradual and the serum levels remain 
below 12.0 Ug/ml. This obseiv.ition is 
quite consistent with our own observa-
tions where in we usually noted transient 
side effects to appear from day 4 on-
wards : our study design having deter-
mined that after day 3 the clo-e of GBZ 
was to be increased from 600 mg/day to 
1000 mg/day stabilization at the higher 
dose, and therefore an expected stabili-
zation of serum levels were enough to 
dispense with the side-effects. Ballenger 
and Post (1980) reported that their 
patients improved on GBZ usually by the 
1st wtvk of treatment and the antimanic 
effects continued throughout the 3 wk 
trial. We have a similar experience, 
when we notice that our patients usually 
improved by day 14 to quite an extent 
and only 2 patients required the dose 
of GBZ to be increased from 1000 to 
1600 mg/day. Improvement, once occu-
rred, continued to be manifest throughout 
the study period. Folks et al. (1982) 
reported that GBZ may have antimanic 
as well as anti-depressant properties. 
Our study, although open in nature, also 
seems to suggest a similar finding. The 
other conclusions drawn by these authors 
viz., (a) GBZ may be effective in some 
lithium non-reponders (b) GBZ and Li 
or GBZ and antidepressants may have 
synergistic efficacy and that (c) GBZ 
may be especially useful in GNS disor-
dered patients with affective syndromes, 
could not obviously be tested owing to the 
study design employed in our study. 
Doubtless, these observations are impor-
tant areas for future investigation. More 
over, it would be surely desirable to 
assess the prophylactic efficacy of GBZ 
in recurrent affective disorders. Reports 
suggesting the importance of GBZ in 
rapid cyclers need to be substantiated 
too. We have already planned a cross-
over study using GBZ and Lithium. 
GBZ, with its antimanic properties- may 28  B. B. SETHI it at. 
be a useful antidepressant in the fact 
that it would l>c free to the problem of 
induction of mania in bipolar depressed 
patients, a hazard reported with other 
antidepressant medication (Wehr & 
Goodwin, 1979). Thus, dually, we feel 
that well-coaiioiled studies are surely 
needed in this area and these would 
throw additional light into the manage-
ment and aotiological understanding of 
Allective disorders. 
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